Science and Art in Orthopedics
Geistlich Ortho
Your trusted partner connecting minds and hands for cartilage and meniscus regeneration.
Dear readers,
May was another intense month with two major congresses. In the first half of the month, we had the pleasure to attend the 21st ESSKA congress, held in Milan. It has been a record congress with 4.391 delegates! Also there is the IFFAS congress in Seoul where we are present with an industry symposium held by well-known foot & ankle surgeons.
When it comes to products, it is with great excitement that we will have a new product in our portfolio in selected markets. Together with the well-established Chondro-Gide? which has received its MDR certification, we are all set for the future.
Will you also be part of our future? We count on you!
Your Geistlich family
Chondro-Gide? Receives MDR Certification
In our first issue of the Geistlich Ortho Gazette in July 2023, we informed you about the status of the MDR submission of Chondro-Gide?.
10 months down the road, we are happy to share that we received the MDR certification for Chondro-Gide?. The MDR’s main aim is to ensure the safety and effectiveness of medical devices on the European market. The MDR increases protection of patient safety, gives better control and accessibility of technical documentation and also increases transparency and traceability of medical devices by new classification rules, stricter requirements for clinical evaluation, technical documentation, postmarket surveillance, vigilance system and a more comprehensive labeling of medical devices.
Geistlich’s work of the past now pays off: “The long term commitment to science and clinical evidence allowed approval under MDR in a timely and efficient way. The MDR requirements may be challenging for products with limited clinical evidence,” states Carrie Hartill , Executive Director Regenerative Technologies at Geistlich. This milestone however is not only a pure formality. It has a direct impact in the daily business of our customers: “Achievement of MDR certification for Chondro-Gide? for cartilage and meniscus repair assures continued availability of this highly versatile and clinically proven Geistlich technology,” Carrie Hartill says. Thus, our customers can be assured that Chondro-Gide? continues to be available as a safe and effective solution to treat their patients.
What can we expect next after this achievement? Carrie Hartill provides a foresight: “The high standards and evidence required to achieve MDR approval also allows Geistlich to expand access to markets outside Europe.”
So, let’s celebrate this important milestone and stay curious to see what is next!
ESSKA 2024 in Milan – Grazie!
When science meets art, one can expect great things happening. Indeed, this was the case in Milan during the 21st ESSKA congress from 08-10 May 2024.
With 4.391 participants from 95 countries, this year’s congress was a record congress of ESSKA as stated by Pietro S. Randelli , ESSKA Congress President. We congratulate the ESSKA president Roland Becker, MD Prof. for making it possible that science met art – a well-chosen theme for Milan as the world capital of fashion and where Leonardo da Vinci created some of his most famous works. Many thanks to the Scientific Programme Chairs Martin Lind , Maristella Saccomanno and Thomas Tischer , for covering the science with such a great selection of sessions.
To cover is also key in cartilage repair. In AMIC?, the cells coming from the bone marrow stimulation are covered with the Chondro-Gide? membrane to protect them from dislocation and shear forces in the joint. This was highlighted by Justus Gille in the Geistlich lunch symposium “Evidence and Innovation: Solutions to Regenerate Damaged Knee Structures”. Also in AMMR? meniscus wrapping, Chondro-Gide? creates a biological chamber in regeneration of complex meniscus tears as shown by Rainer Siebold. Also, Stefano Zaffagnini presented how OrthoPure? XT helps by reducing the need for autograft in ACL revisions.
领英推荐
Thank you Daniel Lee for representing Tissue Regenix Group with this exciting product.
New Kid in the Block: OrthoPure? XT
What is your graft choice in ACL revisions? Sacrificing the contralateral hamstrings? Going for the quadriceps tendon? In any case, there is some donor site morbidity and added surgical time for harvesting. But there might be an alternative solution.
OrthoPure? XT is a porcine tendon graft which has been treated using a patented decellularization processing technology (dCELL?) to remove all viable cells and native components which have the potential to elicit an immune response. This technology gently cleanses the tissue whilst preserving the natural collagen architecture, providing a safe, reliable, easy to use and cost effective alternative to autograft, allograft and synthetics. OrthoPure? XT is available off-the-shelf in predefined diameters and can be stored at room temperature.
We are happy to announce our partnership with Tissue Regenix Group by entering a distribution agreement for OrthoPure? XT in Switzerland and Italy! Geistlich continues to be committed to the pioneering spirit:
David Wemans , Director International Sales & Marketing at Geistlich Ortho says: “Geistlich has a long-standing history as collagen expert and pioneer in joint preservation. We are proud to selectively enlarge our portfolio with this promising collagen technology from Tissue Regenix. OrthoPure? XT is an innovative solution for patients in need for an ACL revision.”
The launch in Switzerland is set up in a way that permits us to gain and document clinical experience. “We are looking forward to seeing the first clinical results in Switzerland from a selected group of regenerative orthopedic specialists,” David Wemans says regarding the launch.
Do you want to learn more? Click here!
Events and Congresses
We are looking forward to seeing you at the following events and congresses:
Past events and congresses - have you been there?
Author: Steven Kramer
VP Regenerative Technologies Geistlich Pharma AG - The Regeneration Company
9 个月Prague
Helping surgeons in cartilage regeneration
9 个月Looking forward already to ESSKA - European Society of Sports Traumatology, Knee Surgery & Arthroscopy 2026 in Prague! ??